Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

NCT01688011 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01688011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01688011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Connect® Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Lead sponsor
Celgene
Phase
Observational
Overall status
Terminated
Start date
December 12, 2013
Completion date
October 18, 2024
Enrollment
2,013 (actual)
Sites
158

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute, myelodysplastic syndromes, primary myelofibrosis